Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 8, 2013, Pages 2792-2797

  Amiram, Miriam ^a   Luginbuhl, Kelli M ^a   Li, Xinghai ^a   Feinglos, Mark N ^b   Chilkoti, Ashutosh ^a  

^a Duke University   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug delivery; Peptide polymers; Sustained release

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; OLIGOMER; PROTEINASE; SYNTHETIC DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY TEMPERATURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ESCHERICHIA COLI; GENE CONSTRUCT; GENE EXPRESSION; GENE SYNTHESIS; GLUCOSE BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; PROTEASE OPERATED DEPOT; PROTEIN CLEAVAGE; PROTEIN PURIFICATION; PROTEIN SECONDARY STRUCTURE; PROTEIN SECRETION;

ANIMALS; BLOOD GLUCOSE; GLUCAGON-LIKE PEPTIDE 1; MALE; MICE; MICE, INBRED C57BL; PEPTIDE HYDROLASES; SPECTROMETRY, FLUORESCENCE; SPECTROSCOPY, NEAR-INFRARED;

EID: 84874245248     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1214518110     Document Type: Article

References (37)

1. Marx V (2005) Watching peptide drugs grown up. Chem Eng News 83 (11):17-24.
2. Edwards CMB, Cohen MA, Bloom SR (1999) Peptides as drugs. QJM 92 (1):1-4.
3. Niu CH, Chiu YY (1998) FDA perspective on peptide formulation and stability issues. J Pharm Sci 87 (11):1331-1334.
4. Banga AK (2005) Parenteral Controlled Delivery and Pharmacokinetics of Therapeutic Peptides and Proteins. Therapeutic Peptides and Proteins (CRC, Boca Raton, FL), pp177-227.
5. Meyer DE, Chilkoti A (2004) Quantification of the effects of chain length and concentration on the thermal behavior of elastin-like polypeptides. Biomacromolecules 5 (3):846-851.
6. Hays NP, Galassetti PR, Coker RH (2008) Prevention and treatment of type 2 diabetes: Current role of lifestyle, natural product, and pharmacological interventions. Pharmacol Ther 118 (2):181-191.
7. Hinnen D, Nielsen LL, Waninger A, Kushner P (2006) Incretin mimetics and DPP-IV inhibitors: New paradigms for the treatment of type 2 diabetes. J Am Board Fam Med 19 (6):612-620.
8. Brubaker PL (2010) Minireview: Update on incretin biology: Focus on glucagon-like peptide-1. Endocrinology 151 (5):1984-1989.
9. Nauck MA (1998) Glucagon-like peptide 1 (GLP-1): A potent gut hormone with a possible therapeutic perspective. Acta Diabetol 35 (3):117-129.
10. Defronzo RA (2009) Banting lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58 (4):773-795.
11. Holst JJ, Vilsbøll T, Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297 (1-2):127-136.
12. Brubaker PL, Drucker DJ (2004) Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145 (6):2653-2659.
13. LeRoith D, Taylor SI, Olefsky JM (2004) Diabetes Mellitus: A Fundamental and Clinical Text (Lippincott Williams & Wilkins, Philadelphia), 3rd Ed, p xviii, 1540 pp.
14. Miranda LP, et al. (2008) Design and synthesis of conformationally constrained glu-cagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity. J Med Chem 51 (9):2758-2765.
15. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD (2004) Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 20 (5):411-417.
16. Madsbad S, et al. (2011) An overview of once-weekly glucagon-like peptide-1 receptor agonists-Available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 13 (5):394-407.
17. Meyer DE, Chilkoti A (2002) Genetically encoded synthesis of protein-based polymers with precisely specified molecular weight and sequence by recursive directional ligation: Examples from the elastin-like polypeptide system. Biomacromolecules 3 (2):357-367.
18. Trabbic-Carlson K, Liu L, Kim B, Chilkoti A (2004) Expression and purification of re-combinant proteins from Escherichia coli: Comparison of an elastin-like polypeptide fusion with an oligohistidine fusion. Protein Sci 13 (12):3274-3284.
19. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (6):2131-2157.
20. Knudsen LB (2004) Glucagon-like peptide-1: The basis of a new class of treatment for type 2 diabetes. J Med Chem 47 (17):4128-4134.
21. Amiram M, Quiroz FG, Callahan DJ, Chilkoti A (2011) A highly parallel method for synthesizing DNA repeats enables the discovery of 'smart' protein polymers. Nat Mater 10 (2):141-148.
22. Yi L, Yin X, Wei D, Ma Y (2006) Expression and purification of exendin-4 dimer in Escherichia coli and its interaction with GLP-1 receptor in vitro. Protein Pept Lett 13 (8):823-827.
23. Betre H, Setton LA, Meyer DE, Chilkoti A (2002) Characterization of a genetically engineered elastin-like polypeptide for cartilaginous tissue repair. Biomacromolecules 3 (5):910-916.
24. Christensen T, et al. (2009) Fusion order controls expression level and activity of elastin-like polypeptide fusion proteins. Protein Sci 18 (7):1377-1387.
25. Kim Y, et al. (1994) FT-IR and near-infrared FT-Raman studies of the secondary structure of insulinotropin in the solid state: Alpha-helix to beta-sheet conversion induced by phenol and/or by high shear force. J Pharm Sci 83 (8):1175-1180.
26. Hupe-Sodmann K, et al. (1995) Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1 (7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58 (3):149-156.
27. Kim JG, et al. (2003) Development and characterization of a glucagon-like peptide 1-albumin conjugate: The ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52 (3):751-759.
28. Wang Q, et al. (2010) Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS ONE 5 (9):e12734.
29. Schellenberger V, et al. (2009) A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 27 (12):1186-1190.
30. Diamant M, et al. (2010) Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial. Lancet 375 (9733):2234-2243.
31. Kwak HH, et al. (2009) Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats. Pharm Res 26 (11):2504-2512.
32. Shive MS, Anderson JM (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28 (1):5-24.
33. Pai SS, Tilton RD, Przybycien TM (2009) Poly (ethylene glycol)-modified proteins: Implications for poly (lactide-co-glycolide)-based microsphere delivery. AAPS J 11 (1):88-98.
34. Burcelin R, Dolci W, Thorens B (1999) Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 48 (2):252-258.
35. Greenfield NJ (2006) Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc 1 (6):2876-2890.
36. Baggio LL, Huang Q, Brown TJ, Drucker DJ (2004) A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-I receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53 (9):2492-2500.
37. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN (1988) Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37 (9):1163-1167.